GemPharmatech

http://www.gempharmatech.com/

Weekly News Amount
Total
${lastRankDetail.pages.length}
Financing ${lastRankDetail.financing_pages.length}
Product ${lastRankDetail.product_pages.length}
Negative ${lastRankDetail.sentiment_pages.length}
GemPharmatech is a high-tech biotechnological enterprise specializing in the research and development of humanized models and drug screening technologies. It has the leading research and development capability of disease models and the research and development center of genetically engineered mice models

Transactions

Funding 2 Fundings
Date Amount Round Relative News
Jul 2019 160 million CNY Series A
Sep 2020 400 million CNY Series B Focusing on the development of model animal, "GemPharmatech" completed the B round of financing exceeding RMB 400 million

Signals

Events ${currentEventsPage.count} Events
Events (${currentEventsPage.count}) Date
Nothing Happens :-(
${e.desp} ${e.date}
News ${ rankDetail.pages.length } News Articles ${currentTimeRange.start} ~ ${currentTimeRange.end}
Article (${rankDetail.pages.length}) Tag
${article.en_title} ${article.tag}
Industry Financing Info

Research

Intelligence 0 Research Briefs

Competition

Competitors 5 Competitors
Company Industry Series Amount Announced Date

KangPoShengWuYiYao

KangPoShengWuYiYao is a biomedical research and development company. Based on a new generation of protein ubiquitination and degradation technologies, KangPoShengWuYiYao focuses on the fields of cancer, autoimmune diseases and inflammation. Its main products are KPG—121 combined with Nzaroamine. Users can treat metastatic castration-resistant prostate cancer

Healthcare

series B

Nearly 100 million CNY

9/8/2019

dMed

dMed is a biomedical innovation service enterprise, focusing on providing pharmaceutical services, expert consultation and business teams for pharmaceutical innovation companies

Healthcare

series B

50 million USD

17/10/2019

BrightGene

BrightGene is committed to the development and production of original new drugs and highly difficult generic drugs to find solutions for clinically unmet needs. BrightGene has made rapid development based on its strong research and development strength, relying on its global registration and commercialization capabilities and cGMP production quality system in line with international standards. It has become a pharmaceutical group covering the whole industry chain of research and development, production and sales

Healthcare

IPO

550 million CNY

8/1/2019

Leto Laboratories

Leto Laboratories is a manufacturer of recombinant protein products. It researches and develops recombinant protein products and drugs through independent research and development of innovative technologies such as high-throughput protein renaturation screening and purification technology platform, fixed-point protein coupling design platform and high-throughput protein drug formulation development technology platform

Artificial Intelligence

Healthcare

series A

Tens of millions CNY

19/3/2019

THERAPEUTICS

THERAPEUTICS is a high-tech biotechnology enterprise dedicated to tumor immune cell therapy. Through the use of advanced life digitalization technology, the vitality of the human immune system against tumors is fully stimulated, and new advanced prevention and treatment schemes targeting tumor-specific antigens are developed to benefit patients. Since 2011, efforts have been made to develop tumor genomes, bio-information technology and tumor immunity

Artificial Intelligence

Healthcare

series A

120 million CNY

20/3/2019